Exelixis (EXEL), Anti-cancer Drug Efficacy 'Up to 74%↓'... $600M Revenue & FDA Approval Expectations

Exelixis (EXEL) announced positive Phase 3 clinical trial results for its anti-cancer drug cabozantinib, showing up to a 74% reduction in the risk of disease progression or death, alongside stable revenue growth and expectations for FDA approval, drawing investor attention.

Catch the next bull catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 50.1%.

Join Telegram channel or scan with phone →